Advertisement

Acne and Rosacea in Skin of Color

  • Sejal K. Shah
  • Andrew F. Alexis
Chapter

Abstract

Acne vulgaris (AV) and rosacea are among the most common skin disorders treated by dermatologists. While both conditions can affect individuals of all racial and ethnic backgrounds, variations in clinical presentation and approaches to treatment exist. This chapter will review the epidemiology, clinical features, and management of AV and rosacea in darkly pigmented patient populations.

Keywords

Benzoyl Peroxide Skin Type Azelaic Acid Intense Pulse Light Topical Retinoid 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Hongcharu W, Taylor CR, Chang Y, Aghassi D, Suthamjariya K, Anderson RR. Topical ALA-photodynamic therapy for the treatment of acne vulgaris. J Invest Dermatol. 2000;115(2): 183–92.PubMedCrossRefGoogle Scholar
  2. 2.
    Halder RM, Holmes YC, Bridgeman-Shah S, Kligman A. A clinical pathological study of acne vulgaris in black females. J Invest Dermatol. 1996;106:888.Google Scholar
  3. 3.
    Alexis AF, Sergay AB, Taylor SC. Common dermatologic disorders in skin of color: a ­comparative practice survey. Cutis. 2007;80(5):387–94.PubMedGoogle Scholar
  4. 4.
    Halder RM, Grimes PE, McLaurin CI, Kress MA, Kenney Jr JA. Incidence of common dermatoses in a predominantly black dermatologic practice. Cutis. 1983;32(4):388–90.PubMedGoogle Scholar
  5. 5.
    Child FJ, Fuller LC, Higgins EM, Du Vivier AW. A study of the spectrum of skin disease occurring in a black population in south-east London. Br J Dermatol. 1999;141(3):512–7.PubMedCrossRefGoogle Scholar
  6. 6.
    Goh CL, Akarapanth R. Epidemiology of skin disease among children in a referral skin clinic in Singapore. Pediatr Dermatol. 1994;11(2):125–8.PubMedCrossRefGoogle Scholar
  7. 7.
    El-Essawi D, Musial JL, Hammad A, Lim HW. A survey of skin disease and skin-related issues in Arab Americans. J Am Acad Dermatol. 2007;56(6):933–8.PubMedCrossRefGoogle Scholar
  8. 8.
    Sanchez MR. Cutaneous diseases in Latinos. Dermatol Clin. 2003;21(4):689–97.PubMedCrossRefGoogle Scholar
  9. 9.
    Callender VD. Acne in ethnic skin: special considerations for therapy. Dermatol Ther. 2004;17(2):184–95.PubMedCrossRefGoogle Scholar
  10. 10.
    Grimes P, Callender V. Tazarotene cream for postinflammatory hyperpigmentation and acne vulgaris in darker skin: a double-blind, randomized, vehicle-controlled study. Cutis. 2006;77(1):45–50.PubMedGoogle Scholar
  11. 11.
    Halder RM. The role of retinoids in the management of cutaneous conditions in blacks. J Am Acad Dermatol. 1998;39(2 Pt 3):S98–103.PubMedCrossRefGoogle Scholar
  12. 12.
    Jacyk WK. Adapalene in the treatment of African patients. J Eur Acad Dermatol Venereol. 2001;15 Suppl 3:37–42.PubMedCrossRefGoogle Scholar
  13. 13.
    Bulengo-Ransby SM, Griffiths CE, Kimbrough-Green CK, Finkel LJ, Hamilton TA, Ellis CN, et al. Topical tretinoin (retinoic acid) therapy for hyperpigmented lesions caused by inflammation of the skin in black patients. N Engl J Med. 1993;328(20):1438–43.PubMedCrossRefGoogle Scholar
  14. 14.
    Gupta AK, Gover MD, Nouri K, Taylor S. The treatment of melasma: a review of clinical trials. J Am Acad Dermatol. 2006;55(6):1048–65.PubMedCrossRefGoogle Scholar
  15. 15.
    Kawashima M, Harada S, Loesche C, Miyachi Y. Adapalene gel 0.1% is effective and safe for Japanese patients with acne vulgaris: a randomized, multicenter, investigator-blinded, controlled study. J Dermatol Sci. 2008;49(3):241–8.PubMedCrossRefGoogle Scholar
  16. 16.
    Fernandez-Obregon A, Davis MW. The BEST study: evaluating efficacy by selected demographic subsets. Cutis. 2003;71(2 Suppl):18–26.PubMedGoogle Scholar
  17. 17.
    Shavin J, Weiss J. Implications of the BEST study. Cutis. 2003;71(2 Suppl):35–6.PubMedGoogle Scholar
  18. 18.
    Taylor SC. Utilizing combination therapy for ethnic skin. Cutis. 2007;80(1 Suppl):15–20.PubMedGoogle Scholar
  19. 19.
    Callender VD, Preston N, Osborn C, Johnson L, Gottschalk RW. A meta-analysis to investigate the relation between Fitzpatrick skin types and tolerability of Adapalene-benzoyl peroxide topical gel in subjects with mild or moderate acne. J Clin Aesthet Dermatol. 2010;3(8):15–9.PubMedGoogle Scholar
  20. 20.
    Gollnick HP, Graupe K, Zaumseil RP. Azelaic acid 15% gel in the treatment of acne vulgaris. Combined results of two double-blind clinical comparative studies. J Dtsch Dermatol Ges. 2004;2(10):841–7.PubMedCrossRefGoogle Scholar
  21. 21.
    Webster G. Combination azelaic acid therapy for acne vulgaris. J Am Acad Dermatol. 2000;43(2 Pt 3):S47–50.PubMedCrossRefGoogle Scholar
  22. 22.
    Draelos ZD, Carter E, Maloney JM, Elewski B, Poulin Y, Lynde C, et al. Two randomized studies demonstrate the efficacy and safety of dapsone gel, 5% for the treatment of acne vulgaris. J Am Acad Dermatol. 2007;56(3):439 e1–10.CrossRefGoogle Scholar
  23. 23.
    Grimes PE. The safety and efficacy of salicylic acid chemical peels in darker racial-ethnic groups. Dermatol Surg. 1999;25(1):18–22.PubMedCrossRefGoogle Scholar
  24. 24.
    Joshi SS, Boone SL, Alam M, Yoo S, White L, Rademaker A, et al. Effectiveness, safety, and effect on quality of life of topical salicylic acid peels for treatment of postinflammatory hyperpigmentation in dark skin. Dermatol Surg. 2009;35(4):638–44. discussion 44.PubMedCrossRefGoogle Scholar
  25. 25.
    Yeung CK, Shek SY, Bjerring P, Yu CS, Kono T, Chan HH. A comparative study of intense pulsed light alone and its combination with photodynamic therapy for the treatment of facial acne in Asian skin. Lasers Surg Med. 2007;39(1):1–6.PubMedCrossRefGoogle Scholar
  26. 26.
    Rojanamatin J, Choawawanich P. Treatment of inflammatory facial acne vulgaris with intense pulsed light and short contact of topical 5-aminolevulinic acid: a pilot study. Dermatol Surg. 2006;32(8):991–6. discussion 6-7.PubMedCrossRefGoogle Scholar
  27. 27.
    Jih MH, Friedman PM, Goldberg LH, Robles M, Glaich AS, Kimyai-Asadi A. The 1450-nm diode laser for facial inflammatory acne vulgaris: dose–response and 12-month follow-up study. J Am Acad Dermatol. 2006;55(1):80–7.PubMedCrossRefGoogle Scholar
  28. 28.
    Paithankar DY, Ross EV, Saleh BA, Blair MA, Graham BS. Acne treatment with a 1,450 nm wavelength laser and cryogen spray cooling. Lasers Surg Med. 2002;31(2):106–14.PubMedCrossRefGoogle Scholar
  29. 29.
    Wang SQ, Counters JT, Flor ME, Zelickson BD. Treatment of inflammatory facial acne with the 1,450 nm diode laser alone versus microdermabrasion plus the 1,450 nm laser: a randomized, split-face trial. Dermatol Surg. 2006;32(2):249–55. discussion 55.PubMedCrossRefGoogle Scholar
  30. 30.
    Tzung TY, Wu KH, Huang ML. Blue light phototherapy in the treatment of acne. Photodermatol Photoimmunol Photomed. 2004;20(5):266–9.PubMedCrossRefGoogle Scholar
  31. 31.
    Pollock B, Turner D, Stringer MR, Bojar RA, Goulden V, Stables GI, et al. Topical aminolaevulinic acid-photodynamic therapy for the treatment of acne vulgaris: a study of clinical efficacy and mechanism of action. Br J Dermatol. 2004;151(3):616–22.PubMedCrossRefGoogle Scholar
  32. 32.
    Wiegell SR, Wulf HC. Photodynamic therapy of acne vulgaris using 5-aminolevulinic acid versus methyl aminolevulinate. J Am Acad Dermatol. 2006;54(4):647–51.PubMedCrossRefGoogle Scholar
  33. 33.
    Berg M, Liden S. An epidemiological study of rosacea. Acta Derm Venereol. 1989;69(5):419–23.PubMedGoogle Scholar
  34. 34.
    Alexis AF. Rosacea in patients with skin of color: uncommon but not rare. Cutis. 2010;86(2): 60–2.PubMedGoogle Scholar
  35. 35.
    Webster G. Rosacea and related disorders. In: Bolognia J, Jorizzo J, Rapini R, editors. Dermatology. 2nd ed. Philadelphia: Mosby Elsevier; 2008. p. 509–16.Google Scholar
  36. 36.
    Adler M. Rosacea in patients with darker skin types. Rosacea Acne Brief. 2002;1(4):1–7.Google Scholar
  37. 37.
    Halder R, Brooks H, Callender V. Acne in ethnic skin. Dermatol Clin. 2003;21(4):609–15.PubMedCrossRefGoogle Scholar
  38. 38.
    Kenney Jr JA. Management of dermatoses peculiar to Negroes. Arch Dermatol. 1965;91:126–9.PubMedCrossRefGoogle Scholar
  39. 39.
    Taylor SC. Epidemiology of skin diseases in ethnic populations. Dermatol Clin. 2003;21(4):601–7.PubMedCrossRefGoogle Scholar
  40. 40.
    Doe PT, Asiedu A, Acheampong JW, Rowland Payne CM. Skin diseases in Ghana and the UK. Int J Dermatol. 2001;40(5):323–6.PubMedCrossRefGoogle Scholar
  41. 41.
    Verhagen AR, Koten JW, Chaddah VK, Patel RI. Skin diseases in Kenya. A clinical and histopathological study of 3,168 patients. Arch Dermatol. 1968;98(6):577–86.PubMedCrossRefGoogle Scholar
  42. 42.
    Wilkin J, Dahl M, Detmar M, Drake L, Feinstein A, Odom R, et al. Standard classification of rosacea: report of the national rosacea society expert committee on the classification and staging of rosacea. J Am Acad Dermatol. 2002;46(4):584–7.PubMedCrossRefGoogle Scholar
  43. 43.
    Crawford GH, Pelle MT, James WD. Rosacea: I. Etiology, pathogenesis, and subtype classification. J Am Acad Dermatol. 2004;51(3):327–41. quiz 42–4.PubMedCrossRefGoogle Scholar
  44. 44.
    Koffi-Aka V, Kouassi AA, D’Horpock FA, Boka NJ, Ehouo F. Rhinophyma in a black African. Rev Laryngol Otol Rhinol (Bord). 2002;123(2):109–10.Google Scholar
  45. 45.
    Khoo CT, Saad MN. Rhinophyma in a Negro: case report. Br J Plast Surg. 1980;33(2):161–3.PubMedCrossRefGoogle Scholar
  46. 46.
    Culp B, Scheinfeld N. Rosacea: a review. Phys Ther. 2009;34(1):38–45.Google Scholar
  47. 47.
    Rosen T, Stone MS. Acne rosacea in blacks. J Am Acad Dermatol. 1987;17(1):70–3.PubMedCrossRefGoogle Scholar
  48. 48.
    Williams HC, Ashworth J, Pembroke AC, Breathnach SM. FACE–facial Afro-Caribbean childhood eruption. Clin Exp Dermatol. 1990;15(3):163–6.PubMedCrossRefGoogle Scholar
  49. 49.
    Pelle MT, Crawford GH, James WD. Rosacea: II. Therapy. J Am Acad Dermatol. 2004;51(4): 499–512. quiz 3–4.PubMedCrossRefGoogle Scholar
  50. 50.
    Korting HC, Schollmann C. Current topical and systemic approaches to treatment of rosacea. J Eur Acad Dermatol Venereol. 2009;23(8):876–82.PubMedCrossRefGoogle Scholar
  51. 51.
    van Zuuren EJ, Gupta AK, Gover MD, Graber M, Hollis S. Systematic review of rosacea treatments. J Am Acad Dermatol. 2007;56(1):107–15.PubMedCrossRefGoogle Scholar
  52. 52.
    Yoo J, Reid DC, Kimball AB. Metronidazole in the treatment of rosacea: do formulation, dosing, and concentration matter? J Drugs Dermatol. 2006;5(4):317–9.PubMedGoogle Scholar
  53. 53.
    Thiboutot D, Thieroff-Ekerdt R, Graupe K. Efficacy and safety of azelaic acid (15%) gel as a new treatment for papulopustular rosacea: results from two vehicle-controlled, randomized phase III studies. J Am Acad Dermatol. 2003;48(6):836–45.PubMedCrossRefGoogle Scholar
  54. 54.
    Elewski BE, Fleischer Jr AB, Pariser DM. A comparison of 15% azelaic acid gel and 0.75% metronidazole gel in the topical treatment of papulopustular rosacea: results of a randomized trial. Arch Dermatol. 2003;139(11):1444–50.PubMedCrossRefGoogle Scholar
  55. 55.
    Ertl GA, Levine N, Kligman AM. A comparison of the efficacy of topical tretinoin and low-dose oral isotretinoin in rosacea. Arch Dermatol. 1994;130(3):319–24.PubMedCrossRefGoogle Scholar
  56. 56.
    Goldman D. Tacrolimus ointment for the treatment of steroid-induced rosacea: a preliminary report. J Am Acad Dermatol. 2001;44(6):995–8.PubMedCrossRefGoogle Scholar
  57. 57.
    Leyden JJ, Thiboutot D, Shalita A. Photographic review of results from a clinical study comparing benzoyl peroxide 5%/clindamycin 1% topical gel with vehicle in the treatment of rosacea. Cutis. 2004;73(6 Suppl):11–7.PubMedGoogle Scholar
  58. 58.
    Ozturkcan S, Ermertcan AT, Sahin MT, Afsar FS. Efficiency of benzoyl peroxide-erythromycin gel in comparison with metronidazole gel in the treatment of acne rosacea. J Dermatol. 2004;31(8):610–7.PubMedGoogle Scholar
  59. 59.
    Colon LE, Johnson LA, Gottschalk RW. Cumulative irritation potential among metronidazole gel 1%, metronidazole gel 0.75%, and azelaic acid gel 15%. Cutis. 2007;79(4):317–21.PubMedGoogle Scholar
  60. 60.
    Erdogan FG, Yurtsever P, Aksoy D, Eskioglu F. Efficacy of low-dose isotretinoin in patients with treatment-resistant rosacea. Arch Dermatol. 1998;134(7):884–5.PubMedCrossRefGoogle Scholar
  61. 61.
    Del Rosso JQ, Webster GF, Jackson M, Rendon M, Rich P, Torok H, et al. Two randomized phase III clinical trials evaluating anti-inflammatory dose doxycycline (40-mg doxycycline, USP capsules) administered once daily for treatment of rosacea. J Am Acad Dermatol. 2007;56(5):791–802.PubMedCrossRefGoogle Scholar
  62. 62.
    Baldwin HE. Systemic therapy for rosacea. Skin Therapy Lett. 2007;12(2):1–5. 9.PubMedGoogle Scholar
  63. 63.
    Hoting E, Paul E, Plewig G. Treatment of rosacea with isotretinoin. Int J Dermatol. 1986;25(10):660–3.PubMedCrossRefGoogle Scholar
  64. 64.
    Battle Jr EF, Hobbs LM. Laser therapy on darker ethnic skin. Dermatol Clin. 2003;21(4):713–23.PubMedCrossRefGoogle Scholar
  65. 65.
    Bhatt N, Alster TS. Laser surgery in dark skin. Dermatol Surg. 2008;34(2):184–94. discussion 94–5.PubMedCrossRefGoogle Scholar
  66. 66.
    Clementoni MT, Gilardino P, Muti GF, Signorini M, Pistorale A, Morselli PG, et al. Intense pulsed light treatment of 1,000 consecutive patients with facial vascular marks. Aesthetic Plast Surg. 2006;30(2):226–32.PubMedCrossRefGoogle Scholar
  67. 67.
    Erisir F, Isildak H, Haciyev Y. Management of mild to moderate rhinophyma with a radiofrequency. J Craniofac Surg. 2009;20(2):455–6.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  1. 1.Department of DermatologySt. Luke’s-Roosevelt Hospital CenterNew YorkUSA
  2. 2.Skin of Color Center, Department of DermatologySt. Luke’s Roosevelt Hospital and Columbia University College of Physicians and SurgeonsNew YorkUSA

Personalised recommendations